AstraZeneca AB (manufacturing, quality control, primary and secondary packaging, batch release; quality control)

The drug is intended for the treatment of adult patients with chronic lymphocytic leukemia (CLL). It may be used as monotherapy or in combination with obinutuzumab, depending on whether the patient has received prior treatment.

Dosage form: tablets, film-coated

ATC: L01EL02